Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF) (LIHFA)

Jens Faber

Status: Completed

Conditions: Low T3 Syndrome; Heart Failure

Treatments: Drug: Liothyronine

Study type: Interventional

Funder types: Other

Identifiers

NCT01481402

HerlevH

Details and patient eligibility

About

Purpose: The purpose of the study is to examine if treatment with liothyronine increases left ventricular ejection fraction (LVEF) in patients with stable, chronic heart failure.

Full description

The patients are examined 3 times. At baseline, after 3 months and after 6 months.After the examination is performed, they begin the study medication while admitted at Dept. of Cardiology, Herlev Hospital, for cardiac monitoring.

Enrollment: 21 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with stable, chronic systolic heart failure
• T3 ≤1.4 nmol/l in two blood samples, TSH is to be normal
• LVEF ≤ 45 % on prior echocardiography

Exclusion criteria

• Established thyroid illness
• Atrial fibrillation/flutter
• More than 20% ventricular extrasystoles
• Severe chronic obstructive lung disorder
• Pregnancy. Pregnancy testing will be done for fertile women
• Age < 18 years

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

21 participants in 2 patient groups, including a placebo group

Placebo-liothyronine

Placebo Comparator group

Description:

3 months of placebo followed by 3 months of Liothyronine treatment.

Treatment:

Drug: Liothyronine

Drug: Liothyronine

Liothyronine-Placebo

Other group

Description:

3 months of Liothyronine treatment followed by 3 months of Placebo treatment.

Treatment:

Drug: Liothyronine

Drug: Liothyronine